Abstract:Abstract Pediatric Low grade gliomas (pLGGs) are largely driven by alterations in the RAS-MAPK pathway. The third most commonly mutated gene in pLGGs is the FGFR1 gene, having alterations including fusions, duplications or missense mutations. Accurate identification of these alterations has become increasingly important as FGFR inhibitors enter the therapeutic space. Here we describe a case of a pLGG patient with an FGFR1 W289_insW290 found through NGS in the tumor at diagnosis, and progression, without additional alterations. This extracellular, third-Ig domain mutation has not been reported. Transcriptional and proteomic profiling of the tumor showed low MAPK and high PIK-AKT pathway activation when compared to other gliomas. Literature review identified disorders of bone formation with similar mutations in the homologous FGFR2 gene. One such mutation, FGFR2 W290G favors inter-receptor disulfide bond formation over the normal intra-receptor disulfide bond. To determine if this insertion is a possible driver mutation in our pLGG case, Alphafold2 protein simulation software was used to make in silico models; quality metrics from both Alphafold2 and VADAR1.8 were used. Structure simulations of the FGFR1 insertion mutant (pLDDT = 81.8) and the mutant FGFR2 W290G (pLDDT = 83.4), were generated and compared to a protein data base, experimentally determined structure of wildtype FGFR1. When monomers of all three structures were aligned using PyMol, the root mean square deviations were < 1.5 indicating the structures are correct or the same. Based on these results we concluded that, like the known FGFR2 mutation, this insertion is predicted to cause hyperactivity by inducing prolonged dimerization due to an aberrant inter-receptor disulfide bond but any structural or functional differences only occur when receptors are dimerized. We are currently generating isogenic cell line models to test this hypothesis and treat these cell lines with inhibitors to determine which treatments might work best for our patient.

Low‐grade BRAF V600E mutant oligodendroglioma‐like tumors of children may show EGFR and MET amplification

29. when Amplification Meets Gene Fusion: Molecular Characterization of PPP1CB-ALK Fusion and Amplification in Pediatric HGG

LGG-36. Analysis of BRAF-related Mutations in Pediatric Low-Grade Glioma

A diverse landscape of FGFR alterations and co-mutations defines novel therapeutic strategies in pediatric low-grade gliomas

Pediatric low-grade glioma in the era of molecular diagnostics

Pediatric Low-Grade Gliomas Can Be Molecularly Stratified for Risk

Genetic Alterations in Uncommon Low-Grade Neuroepithelial Tumors: BRAF , FGFR1 , and MYB Mutations Occur at High Frequency and Align with Morphology

MODL-29. IN SILICO MODELING TO PREDICT ONCOGENICITY AND POTENTIAL TARGETABILITY OF NOVEL FGFR VARIANTS IN PEDIATRIC LOW GRADE GLIOMA

Molecular markers for pediatric low-grade glioma

Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.

Molecular-targeted therapy for childhood low-grade glial and glioneuronal tumors

PATH-34. H3F3A AND TERT PROMOTER MUTATIONS ARE POOR PROGNOSTICATORS IN PEDIATRIC LOW-GRADE GLIOMAS

Molecular and Cellular Pathobiology NovelOncogenic PDGFRA Mutations inPediatricHigh-Grade Gliomas

Oligodendrogliomas in Pediatric and Teenage Patients Only Rarely Exhibit Molecular Markers and Patients Have Excellent Survivals

NovelOncogenicPDGFRAMutationsinPediatricHigh-Grade Gliomas

Clinical, pathologic, and genomic characteristics of two pediatric glioneuronal tumors with a CLIP2::MET fusion

Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.

Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases

Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549–BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification

Genetic Landscape and Its Prognostic Impact in Children With Langerhans Cell Histiocytosis.

HGG-03. PEDIATRIC BITHALAMIC GLIOMA H3K27M NEGATIVE AND EGFR POSITIVE: A DISTINCT ENTITY WITH POTENTIAL SENSIBILITY TO EGFR INHIBITORS